scholarly journals Molecular mechanism of biased signaling in a prototypical G protein–coupled receptor

Science ◽  
2020 ◽  
Vol 367 (6480) ◽  
pp. 881-887 ◽  
Author(s):  
Carl-Mikael Suomivuori ◽  
Naomi R. Latorraca ◽  
Laura M. Wingler ◽  
Stephan Eismann ◽  
Matthew C. King ◽  
...  

Biased signaling, in which different ligands that bind to the same G protein–coupled receptor preferentially trigger distinct signaling pathways, holds great promise for the design of safer and more effective drugs. Its structural mechanism remains unclear, however, hampering efforts to design drugs with desired signaling profiles. Here, we use extensive atomic-level molecular dynamics simulations to determine how arrestin bias and G protein bias arise at the angiotensin II type 1 receptor. The receptor adopts two major signaling conformations, one of which couples almost exclusively to arrestin, whereas the other also couples effectively to a G protein. A long-range allosteric network allows ligands in the extracellular binding pocket to favor either of the two intracellular conformations. Guided by this computationally determined mechanism, we designed ligands with desired signaling profiles.

2020 ◽  
Vol 18 (1) ◽  
Author(s):  
Anna Peters ◽  
Philipp Rabe ◽  
Petra Krumbholz ◽  
Hermann Kalwa ◽  
Robert Kraft ◽  
...  

2019 ◽  
Vol 24 (9) ◽  
pp. 915-927
Author(s):  
P. Heine ◽  
G. Witt ◽  
A. Gilardi ◽  
P. Gribbon ◽  
L. Kummer ◽  
...  

The development of cell-free high-throughput (HT) methods to screen and select novel lead compounds remains one of the key challenges in G protein-coupled receptor (GPCR) drug discovery. Mutational approaches have allowed the stabilization of GPCRs in a purified and ligand-free state. The increased intramolecular stability overcomes two major drawbacks for usage in in vitro screening, the low receptor density on cells and the low stability in micelles. Here, an HT fluorescence polarization (FP) assay for the neurotensin receptor type 1 (NTS1) was developed. The assay operates in a 384-well format and is tolerant to DMSO. From a library screen of 1272 compounds, 12 (~1%) were identified as primary hits. These compounds were validated in orthogonal assay formats using surface plasmon resonance (SPR), which confirmed binding of seven compounds (0.6%). One of these compounds showed a clear preference for the orthosteric binding pocket with submicromolar affinity. A second compound revealed binding at a nonorthosteric binding region and showed specific biological activity on NTS1-expressing cells. A search of analogs led to further enhancement of affinity, but at the expense of activity. The identification of GPCR ligands in a cell-free assay should allow the expansion of GPCR pharmaceuticals with antagonistic or agonistic activity.


2017 ◽  
Vol 112 (3) ◽  
pp. 386a
Author(s):  
George Hedger ◽  
Hsin-Yung Yen ◽  
Idlir Liko ◽  
Carol V. Robinson ◽  
Christian Siebold ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document